Arnd Jacobi1,2, Stephan J Rustenbach1, Matthias Augustin1. 1. Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 2. Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany.
Abstract
BACKGROUND: Psoriasis often requires lifelong therapy, and adherence to treatment is considered a marker for treatment success. Data on the drug survival of biologics in psoriasis patients with comorbidities are lacking. OBJECTIVES: This study was designed to estimate the long-term drug survival rates of different biologic agents in a cohort of psoriasis patients and to evaluate reasons and predictors for treatment adherence. METHODS: Drug survival rates and outcome parameters in psoriasis patients treated with biologic agents were analyzed. RESULTS: A total of 125 treatment periods with adalimumab (n = 37), efalizumab (n = 9), etanercept (n = 55), infliximab (n = 13), and ustekinumab (n = 11) were administered to 67 psoriasis patients. Patients with psoriatic arthritis (P = 0.010) and without comorbidity (P = 0.033) demonstrated significantly greater rates of drug survival. CONCLUSIONS: The overall efficacy of biologic agents is reduced with time. Patients with the comorbidity of metabolic syndrome demonstrate a loss of adherence to biologic treatment.
BACKGROUND:Psoriasis often requires lifelong therapy, and adherence to treatment is considered a marker for treatment success. Data on the drug survival of biologics in psoriasispatients with comorbidities are lacking. OBJECTIVES: This study was designed to estimate the long-term drug survival rates of different biologic agents in a cohort of psoriasispatients and to evaluate reasons and predictors for treatment adherence. METHODS: Drug survival rates and outcome parameters in psoriasispatients treated with biologic agents were analyzed. RESULTS: A total of 125 treatment periods with adalimumab (n = 37), efalizumab (n = 9), etanercept (n = 55), infliximab (n = 13), and ustekinumab (n = 11) were administered to 67 psoriasispatients. Patients with psoriatic arthritis (P = 0.010) and without comorbidity (P = 0.033) demonstrated significantly greater rates of drug survival. CONCLUSIONS: The overall efficacy of biologic agents is reduced with time. Patients with the comorbidity of metabolic syndrome demonstrate a loss of adherence to biologic treatment.
Authors: Kirk Geale; Ingrid Lindberg; Emma C Paulsson; E Christina M Wennerström; Anna Tjärnlund; Wim Noel; Dana Enkusson; Elke Theander Journal: Rheumatol Adv Pract Date: 2020-12-19
Authors: A P Fernandez; E Dauden; S Gerdes; M G Lebwohl; M A Menter; C L Leonardi; M Gooderham; K Gebauer; Y Tada; J P Lacour; L Bianchi; A Egeberg; I Pau-Charles; A M Mendelsohn; S J Rozzo; N N Mehta Journal: J Eur Acad Dermatol Venereol Date: 2022-06-25 Impact factor: 9.228